Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoVector Hires Vice President of R&D for Nanotechnology Cancer Therapeutics

Abstract:
Dr. Paul M. Steed to Head IND Enabling Studies For Next Generation Targeted Cancer Drug

NanoVector Hires Vice President of R&D for Nanotechnology Cancer Therapeutics

RALEIGH, NC | Posted on January 14th, 2009

NanoVector, Inc. announced today that Paul M. Steed, Ph.D. has joined the company as its Vice President of Research and Development. Dr. Steed has 16 years of experience in pharmaceutical R & D, including 10 at Ciba/Novartis and 6 in the biotech industry. He has a thorough understanding of all aspects of pharmaceutical R&D, primarily in the areas of oncology and inflammation/immunology and has numerous high-impact publications. Most recently Dr. Steed served as head of biology for Serenex, which was acquired in April of 2008 by Pfizer, Inc; primarily for its oncology products in clinical and pre-clinical development. At Serenex Dr. Steed managed all aspects of biological research and preclinical biology and helped guide the lead cancer drug SNX-5422 through early development. His background spans small molecules and biologics, a unique combination essential for efficient progress of the NanoVector technology.

"We are delighted to have the opportunity to add someone of Dr. Steed's background to our senior management team," said Albert Bender, Ph.D. CEO. "Leveraging his extensive oncology development experience and leadership, Dr. Steed will accelerate our lead drug time to IND." Dr. Steed added, "I am excited to lead the effort to bring the NanoVector technology to fruition because it clearly can be a breakaway advancement in the treatment of cancer and potentially many other diseases."

####

About NanoVector, Inc.
NanoVector Inc. is commercializing the first biologic-based nanoparticle drug delivery system for the $48B/yr global cancer therapeutics market. Our breakaway technology overcomes all of the hurdles that have impeded chemistry-based nanocarrier systems and is capable of delivering selective targeting of tumors along with the precise intracellular delivery of anti-cancer agents for improved efficacy and fewer unpleasant side effects. The NanoVector technology is based upon a ubiquitous plant virus that has evolved for millions of years to have these ideal drug delivery characteristics, along with the ability to be exposed to mammals (including humans) in a completely benign fashion. To limit uptake to diseased cells, NanoVector has intelligently engineered the surface of the nanocarrier with targeting technology that specifically and exclusively targets tumor cells and the cell components relevant for the treatment/cargo. This technology transcends the long-standing drug paradigm for treating diseases.

For more information, please click here

Contacts:
NanoVector, Inc.
Albert Bender, Ph.D., CEO
919-878-8464

Copyright © Business Wire 2009

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Nanomedicine

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Announcements

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE